Vygon Polskasp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-10-24
Share capital
149,435.00 PLN
Registered address
Francuska 39/6, 03-905 Warszawa, Poland
Electronic delivery address
AE:PL-46166-39131-IAGTG-27

Financials

Revenue history (in m)

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 61 days late). All were audited by a statutory auditor.

  • 202511/05/2026
  • 202413/06/2025
  • 202310/07/2024
  • 202226/06/2023
  • 202114/09/2022
  • 202022/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 10.18mMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD 1.11mMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 8.41mMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 4.95mMedianUSD 608.93kAverageUSD 11.85m

Public procurement

655 tenders recorded as contractor: 228 national ($5,285,189) and 427 EU ($29,490,489).

SubjectAmount
Supply of single-use medical equipment for Szpital Wielospecjalistyczny im. dr. Ludwika Błażka w Inowrocławiu
$20,623
Delivery of single-use equipment
$3,670
Supply of materials for devices owned by Szpital Uniwersytecki.
$29,173

Authorized Representatives

Jan Zdebik – Management Board Member
Ludovic Richard Vitton – President of the Management Board

Manner of representation

The right to sign and make declarations of will on behalf of the company may be exercised by each member of the management board independently.

Ownership

OwnerSharesShare valueStake
Vygon Societe Par Actions Simplifiee
209$40,366.02100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 1994-11-09.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$6,600
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$17,505
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$6,490

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Centrala Farmaceutyczna CefarmS.A.
ITPS.A.
AO East Europesp. z o.o.
MassmedicaS.A.
IMC Impomed CentrumS.A.
Gtm-Mobil M-T T.Walisiewiczsp. k.
Reynolds Medicalsp. z o.o.
Petronafsp. z o.o.
CryoprofilS.A.
Novisc Pharmasp. z o.o.

Change history

DateEvent
2009-07-01Address change
2009-01-21Share capital increase
2009-01-21Name change
2006-01-25Share capital increase
2002-11-28Share capital increase

FAQ

Last updated: 2026-10-07